Epicrispr Biotechnologies, a South San Francisco-based company developing epigenetic editing therapies that control gene expression without cutting DNA, has raised $90 million in Series C funding. The oversubscribed round was co-led by Octagon Capital and Janus Henderson Investors, with participation from Sanofi Ventures and others. The capital will advance its lead candidate EPI-321 toward pivotal studies in facioscapulohumeral muscular dystrophy (FSHD).
Epigenetic Editing Enters Clinical Era
The timing aligns with a shift in gene regulation approaches. Tune Therapeutics raised over $175 million in its Series B in January 2025 for epigenome editing in hepatitis B. Chroma Medicine, now nChroma Bio, secured over $260 million across rounds before merging with Nvelop Therapeutics. Epicrispr's approach using its GEMS platform with the ultracompact CasMINI protein addresses delivery challenges that have limited competitors.
FSHD Lacks Disease-Modifying Options
FSHD patients have no approved therapies that address the root cause of progressive muscle weakness. Current options focus on symptom management. Epicrispr's EPI-321, an AAV-delivered therapy that silences the DUX4 gene epigenetically, has shown early signals of increased lean muscle volume in Phase 1/2 trials, with gains of 0.5 to 1.3 pounds in three evaluable patients at six months.
GEMS Platform Delivers First Proof
Epicrispr's Gene Expression Modulation System combines CasMINI with epigenetic modulators for suppress, activate, or suppress-plus-replace functions. Unlike traditional CRISPR, it avoids DNA breaks. The company reported the first clinical evidence of muscle volume increase from epigenetic editing in humans. CEO Amber Salzman noted the financing supports pivotal development of EPI-321 and broader platform use.
"The proceeds will primarily support the pivotal clinical development of EPI-321, including preparing for registrational studies following our ongoing Phase I/II trial."
Crossover Investors Signal Validation
The round drew generalist crossover funds including Fidelity, Cormorant, and Duquesne Family Office alongside life science specialists. Sanofi Ventures' involvement follows its prior investment in Fulcrum Therapeutics' FSHD program, which ended in Phase 3 failure. This syndicate reflects conviction in epigenetic editing after clinical de-risking.
Epigenetics Market Expands Rapidly
The global epigenetics market stands at $21.9 billion in 2026 and is projected to reach $63.2 billion by 2033, growing at 16.4% CAGR according to Grand View Research. Competitors like Moonwalk Biosciences raised $57 million in 2024, while Omega Therapeutics filed for bankruptcy in 2025 after raising over $200 million. Epicrispr's clinical progress and $213 million total raised position it ahead in the neuromuscular segment.
Leadership Combines Science and Execution
Founder Lei Stanley Qi invented CRISPR activation and interference technologies at Stanford. CEO Amber Salzman brings experience running large budgets at GSK and leading gene therapy companies. The team recently added two VP-level clinical development executives to prepare for later-stage trials.
Path to Registrational Studies
With Phase 1/2 enrollment complete and dose escalation finished, the company plans to engage regulators on pivotal trial design by the end of 2026. It also advances preclinical programs in Duchenne muscular dystrophy and retinitis pigmentosa using the same platform.